860 related articles for article (PubMed ID: 16410657)
1. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
[TBL] [Abstract][Full Text] [Related]
2. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
Ravn P; Clemmesen B; Christiansen C
Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
[TBL] [Abstract][Full Text] [Related]
3. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
4. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
5. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
[TBL] [Abstract][Full Text] [Related]
6. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
Kučukalić-Selimović E; Valjevac A; Hadžović-Džuvo A; Skopljak-Beganović A; Alimanovic-Alagić R; Brković A
Bosn J Basic Med Sci; 2011 Feb; 11(1):41-5. PubMed ID: 21342141
[TBL] [Abstract][Full Text] [Related]
8. Monitoring alendronate therapy for osteoporosis.
Braga de Castro Machado A; Hannon R; Eastell R
J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
[TBL] [Abstract][Full Text] [Related]
9. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
Chaki O; Yoshikata I; Kikuchi R; Nakayama M; Uchiyama Y; Hirahara F; Gorai I
J Bone Miner Res; 2000 Aug; 15(8):1537-44. PubMed ID: 10934652
[TBL] [Abstract][Full Text] [Related]
10. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
11. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
Rosen CJ; Chesnut CH; Mallinak NJ
J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
[TBL] [Abstract][Full Text] [Related]
13. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
Rhee Y; Kang M; Min Y; Byun D; Chung Y; Ahn C; Baek K; Mok J; Kim D; Kim D; Kim H; Kim Y; Myoung S; Kim D; Lim SK
Osteoporos Int; 2006 Dec; 17(12):1801-7. PubMed ID: 17019520
[TBL] [Abstract][Full Text] [Related]
14. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Clin Rheumatol; 2004 Oct; 23(5):383-9. PubMed ID: 15278749
[TBL] [Abstract][Full Text] [Related]
15. Effect of walking exercise on bone metabolism in postmenopausal women with osteopenia/osteoporosis.
Yamazaki S; Ichimura S; Iwamoto J; Takeda T; Toyama Y
J Bone Miner Metab; 2004; 22(5):500-8. PubMed ID: 15316873
[TBL] [Abstract][Full Text] [Related]
16. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
[TBL] [Abstract][Full Text] [Related]
17. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
Colao A; Di Somma C; Loche S; Di Sarno A; Klain M; Pivonello R; Pietrosante M; Salvatore M; Lombardi G
Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Clin Rheumatol; 2007 Feb; 26(2):161-7. PubMed ID: 16565894
[TBL] [Abstract][Full Text] [Related]
19. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
Johnell O; Scheele WH; Lu Y; Reginster JY; Need AG; Seeman E
J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
[TBL] [Abstract][Full Text] [Related]
20. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
Masaryk P; Stancíková M; Letkovská A; Rovenský J
Vnitr Lek; 2002 Oct; 48(10):943-7. PubMed ID: 16737141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]